Autopsy report · NCT04370509
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
Cause of deathFunding or business
“Collaborating sponsor decision”
Life of this trial
- Registered 9 months before it started.
- Ran for about 4 years 1 month before it stopped.
- 6 participants enrolled.
- Results were posted on the registry 8 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Conditions
- Metastatic Clear Cell Renal Cell Carcinoma; Recurrent Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Clear Cell Renal Cell Carcinoma
- Interventions
- Axitinib (VEGF-TKI); Cytoreductive Nephrectomy (CN); Metastasectomy (MET); Pembrolizumab
- Participants
- 6
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease
“Sponsor Decision”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.